A prospective study of aspirin use and the risk of pancreatic cancer in women

Journal of the National Cancer Institute

Volumn 96, Issue 1, 2004, Pages 22-28

  Schernhammer, Eva S ^a,b   Kang, Jae Hee ^a   Chan, Andrew T ^a,c   Michaud, Dominique S ^d   Skinner, Halcyon G ^a,e   Giovannucci, Edward ^a,e   Colditz, Graham A ^a,e,f,g   Fuchs, Charles S ^a,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD CENTER FOR CANCER PREVENTION   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; TOLMETIN;

ADULT; ANAMNESIS; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; NURSE; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TABLET FORMULATION;

EID: 0842280764     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh001     Document Type: Article

References (30)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
3. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
5. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
6. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114.
7. Morrow JD, Roberts LJ. Lipid-derived autoacids. In: Hardman JG, Limbird LE, editors. The pharmacologic basis of therapeutics. New York (NY): McGraw-Hill; 2001. p. 669-85.
8. Perugini RA, McDade TP, Vittimberga FJ Jr, Duffy AJ, Callery MP. Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 2000;4:24-32, discussion 32-3.
9. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase, inhibitors. Cancer 2001;91:333-8.
10. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-71.
11. Willett WC, Browne ML, Bain C, Lipnick RJ, Stampfer MJ, Rosner B, et al. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 1985;122:731-40.
12. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
13. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997;6:49-62.
14. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
15. Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996;156:2255-60.
16. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk, of pancreatic cancer. JAMA 2001;286:921-9.
17. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol 1984;119:837-9.
18. Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002;94:1293-300.
19. Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2002;2:18.
20. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9:119-23.
21. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
22. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
23. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
24. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990;11:393-5.
25. Blomgren KB, Sundstrom A, Steineck G, Genell S, Sjostedt S, Wiholm BE. A Swedish case-control network for studies of drug-induced morbidity-acute pancreatitis. Eur J Clin Pharmacol 2002;58:275-83.
26. O'Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985;12:13-20.
27. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002;51:849-52.
28. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
29. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 1999;266:392-9.
30. Engstrom G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003;52:2097-101.